📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Preliminary Results of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a First-in-Human Trial (CALM) in Adult Patients with CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (2017)

First Author: Graham C

Attributed to: Second Generation Bio-Lentivir Packaging Cell Line for Facile Lentivirus Production funded by EPSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1182/blood.v130.suppl_1.887.887

Publication URI: http://dx.doi.org/10.1182/blood.v130.suppl_1.887.887

Type: Journal Article/Review

Parent Publication: Blood

Issue: Suppl_1